NCT00466232View on ClinicalTrials.gov

Phase I Study of Weekly Topotecan in Combination With Sorafenib in Treatment of Relapsed Small Cell Lung Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

April 30, 2007

Primary Completion Date

December 31, 2009

Study Completion Date

March 31, 2010

Conditions
Small Cell CarcinomaLung Cancer
Interventions
DRUG

Topotecan

4 mg/m2 IV on day 1, 8, 15. Repeat every 28 days.

DRUG

Sorafenib

Dose escalation study at 3 dose levels: 200 mg po daily, 200 mg po bid, 400 mg po bid.

Trial Locations (1)

55416

Park Nicollet Institute, Saint Louis Park

All Listed Sponsors
lead

HealthPartners Institute

OTHER

NCT00466232 - Phase I Study of Weekly Topotecan in Combination With Sorafenib in Treatment of Relapsed Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter